› Forums › General Melanoma Community › PDL-1
- This topic has 9 replies, 3 voices, and was last updated 9 years, 8 months ago by Mat.
- Post
-
- April 6, 2015 at 12:43 pm
Does anyone have the latest on the PDL1 (any updates on effectiveness or its ETA)? In all the fanfare regarding approval of the anti PD-1 drugs, I've lost sight of the PDL-1, which was somewhat behind in the trials but in the same heat. As I recall, the PD L-1 sets the blockade at a different place than the anti PD1 that in theory might be even more effective and have less side effects. There were a couple of firms, including AstraZenica, that were racing to bring these to market. Don't want to appear greedy, but it seems, many could use another option.
- Replies
-
-
- April 6, 2015 at 3:59 pm
Hi G-Samsa, my best guess is that all the big pharma will report in June at ASCO. That way they get lots of press. I watched a presentation from Dr. Omid Hamid from The Angeles Clinic where he talked about several new trials with both Inhibitory and Activating receptors being targeted. Some examples were Lag-3, Tim-3 , Gitr and OX40. Some in combinations with Pd-1 drugs, where from what I have read is where the big break throughs will hopefully be. The video with Dr. Omid Hamid was called " Future therapies for Melanoma" Symposium 2014. Have a nice day!!! Ed
-
- April 6, 2015 at 4:38 pm
Thanks Ed –I suspect you're right about ASCO setting the pace…The trials you mentioned seem like they were at Such an early stage. Was wondering if any of the promising compounds we'd heard so much about over the past couple of years like PDL-1, IDO and some others might come to market in the nearer term–adding to our arsenal.
-
- April 6, 2015 at 6:14 pm
Just saw this article on IDO:
http://cen.acs.org/articles/93/i14/Using-IDO1-Inhibitors-Combat-Cancer.html
-
- April 6, 2015 at 6:14 pm
Just saw this article on IDO:
http://cen.acs.org/articles/93/i14/Using-IDO1-Inhibitors-Combat-Cancer.html
-
- April 6, 2015 at 6:14 pm
Just saw this article on IDO:
http://cen.acs.org/articles/93/i14/Using-IDO1-Inhibitors-Combat-Cancer.html
-
- April 6, 2015 at 4:38 pm
Thanks Ed –I suspect you're right about ASCO setting the pace…The trials you mentioned seem like they were at Such an early stage. Was wondering if any of the promising compounds we'd heard so much about over the past couple of years like PDL-1, IDO and some others might come to market in the nearer term–adding to our arsenal.
-
- April 6, 2015 at 4:38 pm
Thanks Ed –I suspect you're right about ASCO setting the pace…The trials you mentioned seem like they were at Such an early stage. Was wondering if any of the promising compounds we'd heard so much about over the past couple of years like PDL-1, IDO and some others might come to market in the nearer term–adding to our arsenal.
-
- April 6, 2015 at 3:59 pm
Hi G-Samsa, my best guess is that all the big pharma will report in June at ASCO. That way they get lots of press. I watched a presentation from Dr. Omid Hamid from The Angeles Clinic where he talked about several new trials with both Inhibitory and Activating receptors being targeted. Some examples were Lag-3, Tim-3 , Gitr and OX40. Some in combinations with Pd-1 drugs, where from what I have read is where the big break throughs will hopefully be. The video with Dr. Omid Hamid was called " Future therapies for Melanoma" Symposium 2014. Have a nice day!!! Ed
-
- April 6, 2015 at 3:59 pm
Hi G-Samsa, my best guess is that all the big pharma will report in June at ASCO. That way they get lots of press. I watched a presentation from Dr. Omid Hamid from The Angeles Clinic where he talked about several new trials with both Inhibitory and Activating receptors being targeted. Some examples were Lag-3, Tim-3 , Gitr and OX40. Some in combinations with Pd-1 drugs, where from what I have read is where the big break throughs will hopefully be. The video with Dr. Omid Hamid was called " Future therapies for Melanoma" Symposium 2014. Have a nice day!!! Ed
-
- You must be logged in to reply to this topic.